Sector News

Japanese drugmaker buying Sagent to get U.S. beachhead

July 12, 2016
Life sciences

Japan’s Nichi-Iko Pharmaceutical has a pipeline of biosimilars it hopes to sell in the U.S. and figures a beachhead there can only help. To enhance its chances, the drugmaker has struck a deal to acquire U.S. sterile injectables maker Sagent Pharmaceuticals for nearly three-quarters of a billion dollars.

Nichi-Iko today said it will pay $21.75 a share, a 40% premium over the Friday closing share price, for Schaumburg, IL-based Sagent. That adds up to $736 million. It expects the deal to close by the end of September. The Japanese company said it also expects the acquisition to raise its profile in domestic and international generics market and advance the company’s goal of becoming a top 10 global player in generics.

“The U.S. market is a top priority for Nichi-Iko and we believe Sagent is an ideal partner to accelerate our international growth strategy,” Nichi-Iko CEO Yuichi Tamura said in the announcement.

Nichi-Iko isn’t planning any changes to Sagent’s current modus operandi. Its management team remains in charge and will continue to operate Sagent from its headquarters in Schaumburg, IL.

While not a household name in the U.S., Nichi-Iko claims to be the largest generic drug manufacturer in Japan by sales, with annual revenues of about $100 million. It has a portfolio of 50 products and has developed a business of producing drugs for the Japanese market for Western drugmakers.

Sagent Pharmaceuticals jumped into the sterile injectables manufacturing arena a decade ago, backed by private equity money and sporting a unique model. Its initial play was to concentrate on high-demand generics but instead of manufacturing them itself, it put together a network of dozens of contractors to source its ingredients and get its finished products. It has since added a manufacturing plant in China.

The drugmaker earlier this year figured it needed to bulk up to compete and reportedly put itself on the market. A half dozen Indian drugmakers, companies such as Cipla, Lupin and Dr. Reddy’s Laboratories, were said to be eyeing it, but Nichi-Iko swept in to claim the prize.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach